A Phase 3 interventional study of pramipexole 0.125 mg BID and pramipexole 0.0625 mg QD in Tourette Syndrome, sponsored by Boehringer Ingelheim. Terminated at 14 sites in 2 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2014-05-23.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Tourette Syndrome with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Tourette Syndrome · United States.
Among the 139 studies in Tourette Syndrome with a site in United States, this one is the 43rd largest by enrollment of the 105 interventional ones that give a count, is one of 4 that started in 2008, is one of 10 in phase 3, and was the 31st registered.
240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.
Browse Tourette Syndrome studies →20 of the 139 studies in Tourette Syndrome with a site in United States are open now. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 12–17
University of Minnesota · Sites in United States
Ages 12–21
University of Utah · Sites in United States
Ages 8–17
Vanderbilt University Medical Center · Sites in United States
Ages 11–17 · Healthy volunteers
Boston Children's Hospital · Sites in United States
Ages 0–18
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.
This study: 6 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 30 · Phase 3 12 · Phase 4 8
First in 1988; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is above the median of 36 across 183 interventional studies indexed under Tourette Syndrome.
Median enrollment 33 across the 105 interventional studies, 90 across the 33 observational. Of the 106 that completed or were terminated, 45 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 139 have an industry lead sponsor. The 10 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Boehringer Ingelheim has 2 studies filed under Tourette Syndrome — fewer than ten, so there is no comparison to draw.
6 of the studies in Tourette Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05558566Yale UniversityNeurofeedback From the Supplementary Motor Area for Tourette Syndrome | 2026-12-20 |
| NCT01075672Massachusetts General HospitalOutcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals | 2027-01 |
| NCT03914664Vanderbilt University Medical CenterNeural Correlates of Sensory Phenomena in Tourette Syndrome | 2027-02-28 |
| NCT04851678Vanderbilt University Medical CenterLongitudinal Impact of Stressors in Adults With Tourette Syndrome | 2027-03-01 |
| NCT05126888Neurothera Labs Inc.SCI-110 in the Treatment of Tourette Syndrome | 2027-10 |
Add all 6 to your calendar (.ics) → With an account.
Among the 139 studies in Tourette Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this open-label, flexible dose study is to assess the safety and efficacy of pramipexole over a 24-week period in children and adolescents (age 6-17 years inclusive) diagnosed with Tourette Syndrome according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria and who have completed either Study 248.641 (NCT 00681863) or 248.644 (NCT 00558467).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Any of the following lab results at screening:
(Hgb) below lower limit of normal (LLN) which is determined to be clinically significant Basal thyroid stimulating hormone (TSH), triiodothyronine (T3) or thyroxine (T4) clinically significant (at the investigator's discretion) out of normal range at screening (if not caused by substitution therapy according the investigator's opinion) Patients with any clinically significant abnormalities in laboratory parameters at screening at the investigator's discretion.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
all patients to receive one tablet of pramipexole 0.0625 mg BID for first 4 weeks (flexible dosing for all other arms)
Drug: pramipexole 0.0625 mg BID
patients to receive one tablet of pramipexole 0.0625 mg QD
Drug: pramipexole 0.0625 mg QD
patients to receive one tablet of pramipexole 0.125 mg BID
Drug: pramipexole 0.125 mg BID
patients to receive one tablet of pramipexole 0.125 mg TID
Drug: pramipexole 0.125 mg TID
patients to receive one tablet of pramipexole 0.25 mg BID
Drug: pramipexole 0.25 mg BID
titrated dose for those patients whose symptoms were not controlled on the 0.0625 mg BID dose
dose down titrated for those patients unable to tolerate the 0.0625 mg BID dosing
titrated up for those patients whose symptoms were not adequately controlled on 0.125 mg BID dose
titrated for those patients whose symptoms were not adequately controlled on 0.125 mg TID dose
0.0625 mg BID given for first 4 wks of treatment
Patients With Adverse Events Leading to Discontinuation of Trial Drug
Number of patients with Adverse Events leading to discontinuation of trial drug
Time frame: 24 Weeks
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.
Time frame: baseline and week 24
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).
Time frame: baseline and Week 24 (end of treatment visit)
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.
Time frame: baseline and Week 1
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.
Time frame: baseline and Week 2
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.
Time frame: baseline and Week 3
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.
Time frame: baseline and week 4
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.
Time frame: baseline and Week 8
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.
Time frame: baseline and Week 12
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.
Time frame: baseline and Week 16
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.
Time frame: baseline and Week 20
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).
Time frame: baseline and Week 1
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).
Time frame: baseline and Week 2
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).
Time frame: baseline and Week 3
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).
Time frame: baseline and Week 4
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).
Time frame: baseline and Week 8
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).
Time frame: baseline and Week 12
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).
Time frame: baseline and Week 16
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).
Time frame: baseline and Week 20
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).
Time frame: baseline and Week 24
Clinical Global Impressions - Severity of Illness
Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.
Time frame: week 24
Clinical Global Impressions - Severity of Illness, Categorized
Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (among the most extremely ill patients). Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.
Time frame: week 24
Clinical Global Impressions - Improvement
Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).
Time frame: week 1
Clinical Global Impressions - Improvement
Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).
Time frame: week 2
Clinical Global Impressions - Improvement
Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).
Time frame: week 3
Clinical Global Impressions - Improvement
Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).
Time frame: week 4
Clinical Global Impressions - Improvement
Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).
Time frame: week 8
Clinical Global Impressions - Improvement
Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).
Time frame: week 12
Clinical Global Impressions - Improvement
Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).
Time frame: week 16
Clinical Global Impressions - Improvement
Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).
Time frame: week 20
Clinical Global Impressions - Improvement
Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).
Time frame: week 24
Patient Global Impression - Improvement
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
Time frame: week 1
Patient Global Impression - Improvement
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
Time frame: week 2
Patient Global Impression - Improvement
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
Time frame: week 3
Patient Global Impression - Improvement
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
Time frame: week 4
Patient Global Impression - Improvement
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
Time frame: week 8
Patient Global Impression - Improvement
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
Time frame: week 12
Patient Global Impression - Improvement
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
Time frame: week 16
Patient Global Impression - Improvement
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
Time frame: week 20
Patient Global Impression - Improvement
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
Time frame: week 24
Frequency of Patients With Possible Clinically Significant Abnormalities for Laboratory Parameters
Frequency of patients with possible clinically significant abnormalities for laboratory parameters (blood hematology and electrolyte assessments, serum chemistry, including follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol for pubertal female patients, prolactin in all patients, testosterone in pubertal male patients, urine analysis)
Time frame: Baseline and 24 weeks
| Milestone | Pramipexole |
|---|---|
| Started | 45 |
| Completed | 22 |
| Not completed | 23 |
| Withdrew: Adverse event | 1 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Lack of efficacy | 2 |
| Withdrew: Other | 18 |
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.
| Score on a scale | Pramipexole |
|---|---|
| Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale | -9.8 ± 8.9 |
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).
| Score on a scale | Pramipexole |
|---|---|
| Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale | -22.0 ± 21.0 |
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.
| Score on a scale | Pramipexole |
|---|---|
| Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale | -7.2 ± 8.5 |
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.
| Score on a scale | Pramipexole |
|---|---|
| Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale | -8.3 ± 7.7 |
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.
| Score on a scale | Pramipexole |
|---|---|
| Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale | -8.6 ± 8.6 |
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.
| Score on a scale | Pramipexole |
|---|---|
| Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale | -9.3 ± 9.7 |
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.
| Score on a scale | Pramipexole |
|---|---|
| Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale | -10.7 ± 9.4 |
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.
| Score on a scale | Pramipexole |
|---|---|
| Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale | -12.3 ± 9.0 |
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.
| Score on a scale | Pramipexole |
|---|---|
| Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale | -12.4 ± 9.3 |
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.
| Score on a scale | Pramipexole |
|---|---|
| Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale | -11.7 ± 11.3 |
Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.
| Score on a scale | Pramipexole |
|---|---|
| Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale | -9.3 ± 10.4 |
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).
| Score on a scale | Pramipexole |
|---|---|
| Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale | -14.5 ± 18.2 |
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).
| Score on a scale | Pramipexole |
|---|---|
| Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale | -17.4 ± 17.6 |
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).
| Score on a scale | Pramipexole |
|---|---|
| Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale | -18.4 ± 19.8 |
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).
| Score on a scale | Pramipexole |
|---|---|
| Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale | -20.9 ± 21.5 |
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).
| Score on a scale | Pramipexole |
|---|---|
| Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale | -22.4 ± 21.9 |
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).
| Score on a scale | Pramipexole |
|---|---|
| Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale | -27.7 ± 20.9 |
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).
| Score on a scale | Pramipexole |
|---|---|
| Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale | -28.3 ± 20.2 |
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).
| Score on a scale | Pramipexole |
|---|---|
| Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale | -26.7 ± 24.9 |
Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).
| Score on a scale | Pramipexole |
|---|---|
| Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale | -22.0 ± 23.6 |
Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.
| score on a scale | Pramipexole |
|---|---|
| Clinical Global Impressions - Severity of Illness | -1.1 ± 1.1 |
Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (among the most extremely ill patients). Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.
| participants | Pramipexole |
|---|---|
| Improved (change score <= -2) | 11 |
| Unchanged (change score of -1, 0, or +1) | 31 |
| Worsened (change score >= +2) | 0 |
Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).
No measurements were reported for this outcome.
Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).
No measurements were reported for this outcome.
Number of patients with Adverse Events leading to discontinuation of trial drug
| participants | Pramipexole |
|---|---|
| Patients With Adverse Events Leading to Discontinuation of Trial Drug | 1 |
Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).
No measurements were reported for this outcome.
Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).
No measurements were reported for this outcome.
Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).
No measurements were reported for this outcome.
Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).
No measurements were reported for this outcome.
Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).
No measurements were reported for this outcome.
Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).
No measurements were reported for this outcome.
Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).
| participants | Pramipexole |
|---|---|
| Responder (Much improved or Very much improved) | 22 |
| Not Responder | 23 |
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
No measurements were reported for this outcome.
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
No measurements were reported for this outcome.
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
No measurements were reported for this outcome.
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
No measurements were reported for this outcome.
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
No measurements were reported for this outcome.
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
No measurements were reported for this outcome.
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
No measurements were reported for this outcome.
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
No measurements were reported for this outcome.
Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).
| participants | Pramipexole |
|---|---|
| Responder (Much better or Very much better) | 17 |
| Not Responder | 28 |
Frequency of patients with possible clinically significant abnormalities for laboratory parameters (blood hematology and electrolyte assessments, serum chemistry, including follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol for pubertal female patients, prolactin in all patients, testosterone in pubertal male patients, urine analysis)
| participants | Pramipexole |
|---|---|
| Haemoglobin - decrease | 2 |
| Eosinophils - increase | 3 |
| Phosphate - increase | 2 |
| Alkaline phosphatase - increase | 1 |
Collected over up to 24 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pramipexole | — | 1/45 (2.2%) | 35/45 (77.8%) |
| Event | Pramipexole |
|---|---|
| SyncopeNervous system disorders | 1/45 |
| Event | Pramipexole |
|---|---|
| HeadacheNervous system disorders | 9/45 |
| NauseaGastrointestinal disorders | 8/45 |
| FatigueGeneral disorders | 6/45 |
| NasopharyngitisInfections and infestations | 5/45 |
| Abdominal pain upperGastrointestinal disorders | 4/45 |
| VomitingGastrointestinal disorders | 4/45 |
| PyrexiaGeneral disorders | 4/45 |
| HypersensitivityImmune system disorders | 4/45 |
| Upper respiratory tract infectionInfections and infestations | 4/45 |
| Increased appetiteMetabolism and nutrition disorders | 4/45 |
Treated Set (TS) included all patients who were entered, were dispensed study medication and were documented to have taken at least one dose of study medication.
| Age, Continuous(Years) | Pramipexole |
|---|---|
| Mean | 11.8 ± 2.8 |
| Sex: Female, Male(Participants) | Pramipexole |
|---|---|
| Female | 9 |
| Male | 36 |
| Ethnicity (NIH/OMB)(Participants) | Pramipexole |
|---|---|
| Hispanic or Latino | 6 |
| Not Hispanic or Latino | 38 |
| Unknown or Not Reported | 1 |
| Race/Ethnicity, Customized(participants) | Pramipexole |
|---|---|
| Black or African American | 5 |
| White | 40 |
| Duration of Tourettes Syndrome(Participants) | Pramipexole |
|---|---|
| More than 5 years | 10 |
| Less than 1 year | 15 |
| 1 to 5 years | 20 |
| Height(centimeters) | Pramipexole |
|---|---|
| Mean | 152.6 ± 19.4 |
| Weight(kilograms) | Pramipexole |
|---|---|
| Mean | 53.01 ± 21.58 |
| Body mass index(kilograms/square meter) | Pramipexole |
|---|---|
| Mean | 22.064 ± 5.930 |
5 further baseline measures are reported on the registry.
The record gives a start of May 2008 and a primary completion of Oct 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2010, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pramipexole